Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma - Top-Institutions - MDSpire

Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma

  • By

  • Tim Richardson

  • Hishan Tharmaseelan

  • Lukas Frenzel

  • Philipp Gödel

  • Moritz Fürstenau

  • Pascal Nieper

  • Till Braun

  • Daniel Schütte

  • Michael Hallek

  • Christof Scheid

  • Udo Holtick

  • November 15, 2024

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Stem Cell Transplantation
    • Immunology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology/Oncology
    • Stem Cell Transplantation
    • Lymphoma

  • #3

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology/Oncology
    • Stem Cell Transplantation
    • Immunotherapy

  • #4

    University of Cologne
    University of Cologne

    Cologne, North Rhine-Westphalia

    Key Differentiators

    • Hematology
    • Stem Cell Transplantation
    • Clinical Trials

  • #5

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Hematology
    • Stem Cell Transplantation
    • Immunology

Original Source(s)

Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma

  • by Tim Richardson, Hishan Tharmaseelan, Lukas Frenzel, Philipp Gödel, Moritz Fürstenau, Pascal Nieper, Till Braun, Daniel Schütte, Michael Hallek, Christof Scheid, Udo Holtick

  • November 15, 2024

Related Content

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report

Gene- and subtype-dependent prognostic impact of ras pathway mutations in acute myeloid leukemia: a cohort study of 2,500 patients

Fertility preservation and subsequent reproductive outcomes in female pediatric patients with hematologic malignancies